What Has Been The Evolution of the Bexsero Market in Recent Years?
The bexsero market has seen considerable growth due to a variety of factors.
• Recently, the Bexsero market size has experienced an XX (HCAGR). Its projected growth will see it escalate from $XX million in 2024, advancing to $XX million in 2025; this equates to a compound annual growth rate (CAGR) of XX%.
Factors contributing to its growth in the historic period include a rising disease burden, growing demand for meningococcal vaccines, robust healthcare infrastructure, heightened demand for vaccines, and escalating awareness of the disease.
What Is the Forecasted Market Size and Growth Rate for The Bexsero Market By 2029?
The bexsero market is expected to maintain its strong growth trajectory in upcoming years.
• The forecasted expansion of the Bexsero market is predicted to witness XX (FCAGR) in the forthcoming years, ultimately reaching an impressive $XX million in 2029, with a compound annual growth rate (CAGR) of XX%.
The expected growth during this forecast period is largely due to factors such as the increasing occurrences of meningitis, an upsurge in research and development activities, a greater emphasis on preventative healthcare, a rise in immunization programs, and a growing acceptance of vaccines amongst parents. Trends to look out for during this forecast period include advancements in medicare, government-led initiatives, progress in mRNA vaccine technology (representing potential for menB vaccines), breakthroughs in vaccine development, and the formulation of new vaccine delivery techniques.
What Are The Leading Drivers Of Growth In The Bexsero Market?
The escalated cases of meningitis are likely to fuel the expansion of the bexsero market. Meningitis, defined as the irritation of membranes that are protective of the brain and spinal cord due to infection, is increasingly prevalent. This prevalence rise can happen due to a multitude of factors which include augmented infection rates, changes in the area covered by vaccination, reduced immunity and bettered detection and reporting systems. Bexsero assists in safeguarding against meningitis. This is done by activating the immune system into creating antibodies focusing on the Neisseria meningitidis group B bacteria. Consequently, the chances of invasive meningococcal disease, a disease that could cause fatal inflammation of membranes of the brain and spinal cord, are reduced. For example, a report from August 2024 shared by the UK Health Security Agency (UKHSA), a government entity based in the UK, the Meningococcal Reference Unit (MRU) validated 396 cases of invasive meningococcal disease (IMD) in 2022-2023. This was an increase from the 205 cases from 2021-2022. Between 2022 and 2023, the confirmed cases of MenB invasive disease recorded were 356, a drastic leap from the 179 cases in 2021 to 2022 and 61 cases in 2020 to 2021. Hence, the escalating prevalence of meningitis is fuelling the growth of the bexsero market.
What Are The Main Segments Of The Global Bexsero Market?
The bexsero market covered in this report is segmented –
1) By Formulation: Injectable Suspension, Pre-Filled Syringes
2) By Distribution: Hospitals, Pharmacy Stores, Public Health Programs
3) By End User: Adults, Geriatric, Adolescents, Children
Pre-Book The Bexsero Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Bexsero Market?
One major trend in the Bexsero market revolves around the expansion of innovative products - one such example being the meningococcal B vaccine, aimed at offering enhanced protection against different strains within serogroup B. This vaccine is specifically created to combat Neisseria meningitidis serogroup B, a bacterium that is known to cause severe meningococcal disease, encompassing meningitis and bloodstream infections. For example, in July 2024, UK's renowned pharmaceutical company, GlaxoSmithKline (GSK) Plc, introduced the Bexsero vaccine in South Korea. This vaccine includes four critical recombinant proteins - NHBA, NadA, fHbp, and the outer membrane vesicle PorA P1.4 – selected through thorough genetic analysis of meningococcal B. This particular combination stimulates the formation of bactericidal antibodies that are effective against various mechanisms of meningococcal B antigens.
Who Are the Key Players In The Bexsero Market?
Major companies operating in the bexsero market include:
• GlaxoSmithKline plc
What Is The Most Dominant Region In The Bexsero Market?
North America was the largest region in the bexsero market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bexsero market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
